Piscataqua Savings Bank reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.8% in the first quarter, HoldingsChannel reports. The institutional investor owned 25,623 shares of the biopharmaceutical company after selling 1,022 shares during the period. Piscataqua Savings Bank’s holdings in Pfizer were worth $1,326,000 at the end of the last quarter.
A number of other institutional investors and hedge funds have also recently changed their positions in the stock. Rothschild Investment Corp IL increased its stake in Pfizer by 2.9% in the 1st quarter. Rothschild Investment Corp IL now owns 172,809 shares of the biopharmaceutical company valued at $8,946,000 after buying an additional 4,829 shares last quarter. TimeScale Financial Inc. increased its stake in Pfizer by 3.6% in the 1st quarter. TimeScale Financial Inc. now owns 7,230 shares of the biopharmaceutical company valued at $374,000 after buying an additional 252 shares last quarter. PDS Planning Inc increased its stake in Pfizer by 34.7% in the 1st quarter. PDS Planning Inc now owns 18,991 shares of the biopharmaceutical company valued at $983,000 after buying 4,888 additional shares last quarter. Annex Advisory Services LLC increased its stake in Pfizer by 23.6% in the 1st quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company valued at $532,000 after buying 1,966 additional shares last quarter. Finally, IFM Investors Pty Ltd increased its stake in Pfizer shares by 21.2% in the 1st quarter. IFM Investors Pty Ltd now owns 878,033 shares of the biopharmaceutical company valued at $45,456,000 after buying an additional 153,642 shares last quarter. Institutional investors hold 66.50% of the company’s shares.
EFP has been the subject of several recent research reports. SVB Leerink launched a hedge on Pfizer shares in a Monday, May 23 report. They issued a “market performance” rating and a price target of $55.00 for the company. StockNews.com moved Pfizer shares from a “buy” rating to a “strong buy” rating in a Tuesday, April 19 report. Citigroup raised its price target on Pfizer shares from $46.00 to $57.00 and gave the company a “neutral” rating in a Tuesday, April 5 report. JPMorgan Chase & Co. set a price target of $57.00 on Pfizer shares in a research note Tuesday. Finally, Morgan Stanley began covering Pfizer shares in a research note on Wednesday, April 6. They set an “equal weight” rating and a price target of $55.00 for the company. Nine analysts gave the stock a hold rating, ten gave the company a buy rating and one gave the company’s stock a strong buy rating. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $57.26.
PFE stock opened at $50.66 on Wednesday. The company’s fifty-day simple moving average is $50.49 and its 200-day simple moving average is $52.20. The company has a market cap of $284.25 billion, a P/E ratio of 11.62, a price-to-earnings growth ratio of 0.63, and a beta of 0.76. The company has a debt ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13. Pfizer Inc. has a 12-month low of $38.82 and a 12-month high of $61.71.
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly results on Tuesday, May 3. The biopharmaceutical company reported earnings per share (EPS) of $1.62 for the quarter, missing analyst consensus estimates of $1.66 per ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company posted revenue of $25.66 billion for the quarter, versus $24.73 billion expected by analysts. During the same period last year, the company posted earnings per share of $0.93. The company’s quarterly revenue increased 76.8% year over year. As a group, sell-side analysts expect Pfizer Inc. to post earnings per share of 6.61 for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Wednesday, June 29 will receive a dividend of $0.40 per share. This represents a dividend of $1.60 on an annualized basis and a yield of 3.16%. The ex-dividend date is Thursday July 28. Pfizer’s dividend payout ratio (DPR) is currently 36.70%.
In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of the company in a trade on Tuesday, June 7. The shares were sold at an average price of $53.96, for a total transaction of $227,603.28. Following the completion of the transaction, the Senior Vice President now directly owns 10,846 shares of the company, valued at $585,250.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. Additionally, SVP Jennifer B. Damico sold 4,000 shares of the company in a transaction on Monday, May 16. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the transaction, the senior vice president now owns 15,064 shares of the company, valued at $760,732. The disclosure of this sale can be found here. Insiders have sold 41,126 shares of the company worth $2,075,003 in the past three months. 0.05% of the shares are currently held by insiders.
Pfizer Company Profile (Get an evaluation)
Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceuticals worldwide. It offers drugs and vaccines in various therapeutic areas, including cardiovascular, metabolic and women’s health under the Premarin Family and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs, and oral COVID-19 treatment under the brands Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.
Want to see which other hedge funds hold PFEs? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Pfizer Inc. (NYSE:PFE – Get Rating).
Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.